僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Mavezelimab （MK-4280） is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer （CRC） research combined with the PD-L1 inhibitor Pembrolizumab （HY-P9902）